Purpose Motivated by stagnant new drug approval rates, this study explores the drivers and barriers to drug discovery to extract policy-relevant advice. Methods As part of a doctoral dissertation, an online survey was administered to drug discovery experts between July and November 2017. Respondents came from patents, startup managers/founders, conference speakers, consultants, and LinkedIn profiles, contingent on finding respondent emails from a web search. Respondents ranked drivers and barriers to drug discovery and judged R&D and drug approval trends. Results Pooling responses based on frequency of mentions, indicate that respondents deem Bskilled R&D scientists^, BR&D investments^,and Bgood R&D management^ as the top three drivers of drug discovery. The Bdepth^ of specialized knowledge is mentioned more than the Bdiversity^ of knowledge available to the discovery team. Likewise, Bcomplex clinical trials^, Bcompanies pursuing the same drug targets^,and Bdesigning drug substances with a single or narrow therapeutic benefits^ are top ranked barriers to drug discovery. The majority view is that R&D spending has been stagnant for the past decade. New drug approval trend is judged to be improving in the past 5 years. Ninety percent of respondents believe their responses are gener- alizable to other therapeutic areas, indicating instrument’s validity in capturing
Journal of Pharmaceutical Innovation – Springer Journals
Published: Jun 4, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
All the latest content is available, no embargo periods.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud